167 related articles for article (PubMed ID: 37185307)
1. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations.
Urrutia S; Li Z; Almanza E; Bataller A; Kanagal-Shamanna R; Senapati J; Sasaki K; Chien K; Montalban-Bravo G; DiNardo C; Borthakur G; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2023 Jun; 37(6):1397-1400. PubMed ID: 37185307
[No Abstract] [Full Text] [Related]
2. Spliceosomal factor mutations and mis-splicing in MDS.
Hershberger CE; Daniels NJ; Padgett RA
Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
[TBL] [Abstract][Full Text] [Related]
3. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
Liu YC; Illar GM; Bailey NG
J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
[TBL] [Abstract][Full Text] [Related]
5. SF3B1 mutant myelodysplastic syndrome: Recent advances.
Pellagatti A; Boultwood J
Adv Biol Regul; 2021 Jan; 79():100776. PubMed ID: 33358369
[TBL] [Abstract][Full Text] [Related]
6. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling.
Pollyea DA; Harris C; Rabe JL; Hedin BR; De Arras L; Katz S; Wheeler E; Bejar R; Walter MJ; Jordan CT; Pietras EM; Alper S
Haematologica; 2019 Sep; 104(9):e388-e392. PubMed ID: 30846499
[No Abstract] [Full Text] [Related]
8. Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts.
Huber S; Haferlach T; Meggendorfer M; Hutter S; Hoermann G; Summerer I; Fuhrmann I; Baer C; Kern W; Haferlach C
Leukemia; 2023 Feb; 37(2):500-502. PubMed ID: 36463343
[No Abstract] [Full Text] [Related]
9. Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Chesnais V; Kosmider O; Damm F; Itzykson R; Bernard OA; Solary E; Fontenay M
Oncotarget; 2012 Nov; 3(11):1284-93. PubMed ID: 23327988
[TBL] [Abstract][Full Text] [Related]
10. AI-assisted proofreading of RNA splicing.
Guerra-Moreno Á; Valcárcel J
Genes Dev; 2023 Dec; 37(21-24):945-947. PubMed ID: 38092520
[TBL] [Abstract][Full Text] [Related]
11. Promoting spliceosome assembly for therapeutic intent.
Lu B; Abdel-Wahab O
Trends Pharmacol Sci; 2021 Dec; 42(12):981-983. PubMed ID: 34602305
[TBL] [Abstract][Full Text] [Related]
12. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Targeting of RNA Splicing in Cancer.
Bonner EA; Lee SC
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
[TBL] [Abstract][Full Text] [Related]
14. Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.
Pellagatti A; Armstrong RN; Steeples V; Sharma E; Repapi E; Singh S; Sanchi A; Radujkovic A; Horn P; Dolatshad H; Roy S; Broxholme J; Lockstone H; Taylor S; Giagounidis A; Vyas P; Schuh A; Hamblin A; Papaemmanuil E; Killick S; Malcovati L; Hennrich ML; Gavin AC; Ho AD; Luft T; Hellström-Lindberg E; Cazzola M; Smith CWJ; Smith S; Boultwood J
Blood; 2018 Sep; 132(12):1225-1240. PubMed ID: 29930011
[No Abstract] [Full Text] [Related]
15. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
[TBL] [Abstract][Full Text] [Related]
16. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
[TBL] [Abstract][Full Text] [Related]
17. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
[TBL] [Abstract][Full Text] [Related]
18. Tumor suppressor microRNAs are downregulated in myelodysplastic syndrome with spliceosome mutations.
Aslan D; Garde C; Nygaard MK; Helbo AS; Dimopoulos K; Hansen JW; Severinsen MT; Treppendahl MB; Sjø LD; Grønbæk K; Kristensen LS
Oncotarget; 2016 Mar; 7(9):9951-63. PubMed ID: 26848861
[TBL] [Abstract][Full Text] [Related]
19. Emerging roles of spliceosome in cancer and immunity.
Yang H; Beutler B; Zhang D
Protein Cell; 2022 Aug; 13(8):559-579. PubMed ID: 34196950
[TBL] [Abstract][Full Text] [Related]
20. Somatic
Foy A; McMullin MF
J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
